Question 52

The Qsymia REMS program is intended to help prevent embryo-fetal exposure.

The Qsymia REMS program is designed specifically to mitigate the risks associated with embryo-fetal exposure during pregnancy. This is crucial given the potential teratogenic effects of the medication contained within Qsymia.

A) embryo-fetal exposure.

This option is correct as the Qsymia REMS program is explicitly implemented to prevent embryo-fetal exposure. The medication has been shown to pose risks to fetal development, making this a central focus of the REMS initiative.

B) respiratory depression.

While respiratory depression is a serious concern with certain medications, it is not the primary focus of the Qsymia REMS program. This option is incorrect because the program is specifically aimed at addressing risks related to pregnancy and fetal health rather than respiratory issues.

C) fatal hemorrhage.

Fatal hemorrhage is not directly associated with the use of Qsymia, and thus it is not a target of the REMS program. This choice is incorrect, as the program focuses on preventing risks to fetal development rather than bleeding complications.

D) vision loss.

Vision loss is not a primary concern addressed by the Qsymia REMS program. This option is incorrect as the program is not aimed at preventing visual impairment but rather at safeguarding against risks associated with embryo-fetal exposure.

Conclusion

In summary, the Qsymia REMS program is focused on preventing embryo-fetal exposure due to the potential risks associated with the medication in pregnant individuals. The other options, while they may represent significant health concerns in different contexts, do not align with the primary objectives of the REMS program in relation to Qsymia.